203 related articles for article (PubMed ID: 31450065)
1. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors.
Ma W; Wang Y; Chu D; Yan H
J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
3. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
4. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
5. 4D-QSAR and MIA-QSAR Studies of Aminobenzimidazole Derivatives as Fourth-generation EGFR Inhibitors.
Jia X; Wei C; Tian N; Yan H; Wang H
Med Chem; 2024; 20(2):140-152. PubMed ID: 37957859
[TBL] [Abstract][Full Text] [Related]
6. 4D-LQTA-QSAR and docking study on potent Gram-negative specific LpxC inhibitors: a comparison to CoMFA modeling.
Ghasemi JB; Safavi-Sohi R; Barbosa EG
Mol Divers; 2012 Feb; 16(1):203-13. PubMed ID: 22127637
[TBL] [Abstract][Full Text] [Related]
7. Molecular Dynamics Guided Receptor Independent 4D QSAR Studies of Substituted Coumarins as Anticancer Agents.
Patil R; Sawant S
Curr Comput Aided Drug Des; 2015; 11(1):39-50. PubMed ID: 26081557
[TBL] [Abstract][Full Text] [Related]
8. Benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one derivatives as Aurora A kinase inhibitors: LQTA-QSAR analysis and detailed systematic validation of the developed model.
Kanhed AM; Dash RC; Parmar N; Das TK; Giridhar R; Yadav MR
Mol Divers; 2015 Nov; 19(4):965-74. PubMed ID: 26183841
[TBL] [Abstract][Full Text] [Related]
9. LQTA-QSAR: a new 4D-QSAR methodology.
Martins JP; Barbosa EG; Pasqualoto KF; Ferreira MM
J Chem Inf Model; 2009 Jun; 49(6):1428-36. PubMed ID: 19422246
[TBL] [Abstract][Full Text] [Related]
10. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Pery N; Rizvi NB; Shafiq MI
J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
[TBL] [Abstract][Full Text] [Related]
11. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
12. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor.
Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562
[No Abstract] [Full Text] [Related]
13. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
14. Four-dimensional structure-activity relationship model to predict HIV-1 integrase strand transfer inhibition using LQTA-QSAR methodology.
de Melo EB; Ferreira MM
J Chem Inf Model; 2012 Jul; 52(7):1722-32. PubMed ID: 22657398
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
16. Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors.
Balasubramanian PK; Balupuri A; Kang HY; Cho SJ
BMC Syst Biol; 2017 Mar; 11(Suppl 2):6. PubMed ID: 28361711
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors.
Hu Z; Lin Q; Liu H; Zhao T; Yang B; Tu G
Mol Divers; 2022 Apr; 26(2):757-768. PubMed ID: 33625673
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
[TBL] [Abstract][Full Text] [Related]
19. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors.
Wang J; Ran T; Chen Y; Lu T
Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311
[TBL] [Abstract][Full Text] [Related]
20. CORAL: Monte Carlo based global QSAR modelling of Bruton tyrosine kinase inhibitors using hybrid descriptors.
Ahmadi S; Lotfi S; Afshari S; Kumar P; Ghasemi E
SAR QSAR Environ Res; 2021 Dec; 32(12):1013-1031. PubMed ID: 34875951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
